Shares of Health Care sector company Ventyx Biosciences moved -80.8% today, and are now trading at a price of $2.71. The small-cap stock's daily volume was 19,254,655 compared to its average volume of 761,804. The S&P 500 index returned a 0.0% performance.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company is based in Encinitas and has 91 full time employees. Its market capitalization is $159,581,664.
10 analysts are following Ventyx Biosciences and have set target prices ranging from $46.0 to $77.0 per share. On average, they have given the company a rating of buy. At today's prices, VTYX is trading -95.04% away from its average analyst target price of $54.6 per share.
Over the last year, VTYX shares have gone down by -89.0%, which represents a difference of -104.0% when compared to the S&P 500. The stock's 52 week high is $47.25 per share and its 52 week low is $2.37. Ventyx Biosciences has averaged free cash flows of $-96554666.7 over the last 3 years, with a mean growth rate of -57.8%. It is likely that the stock will keep following its current negative performance trend while the underlying business is experiencing such poor cash flows.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | -151,456 | 464 | -151,920 | -53.38 |
| 2022 | -98,771 | 275 | -99,046 | -155.95 |
| 2021 | -38,650 | 48 | -38,698 |
